Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envafolimab + suvemcitug + oxaliplatin + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- 3D Medicines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous, Intra-arterial
01
Overview
Envafolimab + suvemcitug + oxaliplatin + 5-fluorouracil is an investigational combination regimen being evaluated for the conversion therapy of potentially resectable hepatocellular carcinoma (HCC). The regimen integrates two biologics — envafolimab, a subcutaneously administered anti-PD-L1 monoclonal antibody, and suvemcitug, an anti-VEGF monoclonal antibody — with a hepatic arterial infusion chemotherapy (HAIC) backbone consisting of oxaliplatin and 5-fluorouracil (the FOLFOX regimen). This multi-modality approach is designed to enhance anti-tumor activity through simultaneous immune checkpoint blockade, inhibition of angiogenesis, and localized cytotoxic chemotherapy. The primary goal of this conversion therapy is to downstage tumors in patients with advanced or borderline-resectable HCC to a state where radical surgical resection becomes feasible.
- Other names
- Envafolimab + Suvemcitug + HAICEnvafolimab + Suvemcitug + FOLFOXKN035 + KL-A167 + HAICKN035 + KL-A167 + FOLFOX
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on envafolimab + suvemcitug + oxaliplatin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envafolimab + suvemcitug + oxaliplatin + 5-fluorouracil.